FDA approves new drug Rasonque to treat advanced pancreatic cancer
Summary
The US Food and Drug Administration (FDA) approved a new drug called Rasonque to treat advanced pancreatic cancer. The drug, made by Revolution Medicines, is a daily pill that was shown to double survival rates in patients with metastatic pancreatic cancer.Key Facts
- Rasonque is approved for patients with metastatic pancreatic cancer who have had prior treatment or can't use combination chemotherapy.
- The pill works by blocking several forms of the RAS protein, which promotes tumor growth in many pancreatic cancers.
- A large clinical trial showed that Rasonque doubled survival rates for advanced pancreatic cancer patients.
- The drug costs $39,800 for a 30-day supply in the United States.
- The FDA used an expedited review process to approve Rasonque faster than usual, reducing the timeline to a few months.
- The drug was available earlier via the FDA’s compassionate use program for patients with serious conditions.
- Investor interest in Revolution Medicines increased, with the company's stock rising 166% this year.
- Analysts predict that Rasonque could generate billions of dollars in global sales and significantly impact pancreatic cancer treatment.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
